Details of the Drug Combinations

General Information of This Drug (ID: DMTS85L)

Drug Name
Capecitabine   DMTS85L
Synonyms
Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Colon adenocarcinoma N.A. Approved [1]
Colorectal cancer 2B91.Z Approved [2]
Metastasis from malignant tumor of colon N.A. Approved [1]
Rectal adenocarcinoma 2B92 Approved [1]
Breast cancer 2C60-2C65 Phase 3 [2]
Colon cancer 2B90.Z Investigative [1]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

85 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
ABT-888 + Capecitabine DCAW4KX ABT-888 Locally Advanced Rectal Cancer [3]
Aflibercept + Capecitabine DCSYKQV Aflibercept Metastatic Colorectal Cancers [4]
Alpelisib + Capecitabine DCDPQPJ Alpelisib Metastatic Breast Cancer [5]
Alpelisib + Capecitabine DC52PIO Alpelisib Rectal Cancer [6]
Bexarotene + Capecitabine DC9T1H5 Bexarotene Metastatic Triple-Negative Breast Carcinoma [7]
Bosutinib + Capecitabine DCIN2ZE Bosutinib Advanced Breast Cancer (Parts 1 and 2) [8]
Capecitabine + Vorinostat DC0RQKZ Vorinostat Unspecified Adult Solid Tumor, Protocol Specific [9]
Capecitabine + Hydroxychloroquine DC7K2S6 Hydroxychloroquine Pancreatic Cancer [10]
Capecitabine + Vinorelbine DCCMX4E Vinorelbine Breast Cancer [11]
Capecitabine + Perifosine DCGI2GR Perifosine Colon Cancer [12]
Capecitabine + Dexpanthenol DCGNOCH Dexpanthenol Breast Cancer [13]
Capecitabine + Dasatinib DCRE56F Dasatinib Advanced Breast Cancer [14]
Capecitabine + Vorinostat DCUC1UP Vorinostat Paranasal Sinus Squamous Cell Carcinoma [15]
Capecitabine + CHR-2797 DC0FV9N CHR-2797 Pancreatic Cancer [16]
Capecitabine + Pyrotinib DCGPYQN Pyrotinib HER2 Positive Metastatic Breast Cancer [17]
CB-839 + Capecitabine DCBSGJK CB-839 Colorectal Cancer [18]
Celecoxib + Capecitabine DCJQ5YV Celecoxib Breast Cancer [19]
Celecoxib + Capecitabine DCYFGXO Celecoxib Colorectal Cancer [20]
Cyclophosphamide + Capecitabine DCQZLUL Cyclophosphamide Breast Cancer [21]
Docetaxel + Capecitabine DCCWXZ6 Docetaxel Breast Cancer [22]
Docetaxel + Capecitabine DCLDWI8 Docetaxel Esophageal Cancer [23]
Enzastaurin + Capecitabine DC67GEC Enzastaurin Breast Cancer [24]
Eribulin + Capecitabine DC98M4I Eribulin Metastatic Breast Cancer [25]
Erlotinib + Capecitabine DCHPW08 Erlotinib Pancreatic Cancer [26]
Everolimus + Capecitabine DC96HAK Everolimus Metastatic Gastric Cancer [27]
EXISULIND + Capecitabine DCAO9ZT EXISULIND Breast Neoplasms [28]
Fulvestrant + Capecitabine DCL8ASK Fulvestrant Metastatic Breast Cancer [29]
GDC-0980/RG7422 + Capecitabine DCROML6 GDC-0980/RG7422 Solid Cancers [30]
Gefitinib + Capecitabine DC9RNOF Gefitinib Unspecified Adult Solid Tumor, Protocol Specific [31]
Gemcitabine + Capecitabine DCYTOJ2 Gemcitabine Pancreatic Cancer [32]
HKI-272 + Capecitabine DCYKG3X HKI-272 Breast Cancer [33]
Imatinib + Capecitabine DC6LV9E Imatinib Breast Cancer [34]
Indibulin + Capecitabine DCCEASB Indibulin Advanced Solid Tumors [35]
Irinotecan + Capecitabine DC1CQZK Irinotecan Colorectal Cancer [36]
Ixabepilone + Capecitabine DC5T6JM Ixabepilone Breast Cancer [37]
Ixabepilone + Capecitabine DCY6JTI Ixabepilone Breast Cancer [38]
Lapatinib + Capecitabine DCEJ7BH Lapatinib Breast Cancer [39]
Larotaxel + Capecitabine DCAI3TM Larotaxel Breast Cancer [40]
Lenvatinib + Capecitabine DC43E9B Lenvatinib Advanced Cancer [41]
Lurbinectedin + Capecitabine DCX4FUD Lurbinectedin Metastatic Breast Cancer [42]
Mitoxantrone + Capecitabine DC1VIXA Mitoxantrone Breast Cancer [43]
Momelotinib + Capecitabine DCV1EC5 Momelotinib Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma [44]
Napabucasin + Capecitabine DCSV088 Napabucasin Colorectal Cancer [45]
Oxaliplatin + Capecitabine DCA8J4B Oxaliplatin Esophageal Cancer [46]
Oxaliplatin + Capecitabine DCBV3H2 Oxaliplatin Colorectal Cancer [47]
Panobinostat + Capecitabine DC1UT3T Panobinostat Breast Cancer [48]
Regorafenib + Capecitabine DCNQWSH Regorafenib Rectal Cancer [49]
Ruxolitinib + Capecitabine DCQHZUU Ruxolitinib Pancreatic Cancer [50]
Selumetinib + Capecitabine DCCY955 Selumetinib Non-Metastatic Adenocarcinoma of the Rectum [51]
SNDX-275 + Capecitabine DCXQ2KK SNDX-275 Metastatic Breast Cancer [52]
Sunitinib + Capecitabine DCUKVMF Sunitinib Advanced/Metastatic Breast Cancer [53]
Sunitinib + Capecitabine DCVMILF Sunitinib Breast Cancer [54]
Temozolomide + Capecitabine DCHOEN1 Temozolomide Neuroendocrine Tumors [55]
Temozolomide + Capecitabine DCPHQL6 Temozolomide Glioblastoma Multiforme (GBM) [56]
Tesetaxel + Capecitabine DCU1RP0 Tesetaxel Gastric Carcinoma [57]
Tucatinib + Capecitabine DC46KGK Tucatinib HER2 Positive Metastatic Breast Cancers [58]
Valproic Acid + Capecitabine DCRRO6O Valproic Acid Colorectal Cancer [59]
Varlitinib + Capecitabine DCRK77X Varlitinib Advanced or Metastatic Biliary Tract Cancer [60]
Venetoclax + Capecitabine DCH24X1 Venetoclax Breast Cancer [61]
Vinflunine + Capecitabine DCCWW4I Vinflunine Breast Cancer [62]
Zarnestra + Capecitabine DC40N2I Zarnestra Recurrent Breast Cancer [63]
Al3818 + Capecitabine DCZNDX4 Al3818 Metastatic Triple-Negative Breast Cancer [64]
Capecitabine + GDC-0068 DCEW2GK GDC-0068 Triple Negative Breast Cancer [65]
Capecitabine + Andrographolide DCFM9Q2 Andrographolide Colorectal Neoplasms [66]
Capecitabine + Leucovorin DCLU65L Leucovorin Liver Metastases [67]
Digoxin + Capecitabine DCA8BX6 Digoxin Metastatic Breast Cancer [68]
Eribulin + Capecitabine DC404H3 Eribulin Metastatic Breast Cancer [69]
Gemcitabine + Capecitabine DCS4MQD Gemcitabine Pancreatic Cancer [70]
Irinotecan + Capecitabine DC1M9DP Irinotecan Rectal Cancer [71]
Mitomycin + Capecitabine DCC64EG Mitomycin Carcinoma of Anal Canal [72]
Nintedanib + Capecitabine DCRCJCE Nintedanib Colorectal Neoplasms [73]
Oxaliplatin + Capecitabine DCCEH20 Oxaliplatin Gastric Cancer [74]
Paclitaxel + Capecitabine DCJ59FN Paclitaxel Breast Cancer [75]
Paclitaxel + Capecitabine DCMC8M0 Paclitaxel Gastric Adenocarcinoma [76]
Regorafenib + Capecitabine DCZEKYJ Regorafenib Pancreatic Cancer [77]
Rivoceranib + Capecitabine DCGJFQZ Rivoceranib Hepatocellular Carcinoma [78]
Rivoceranib + Capecitabine DCH9N6H Rivoceranib Biliary Carcinoma [79]
Tesetaxel + Capecitabine DCEWC7E Tesetaxel Breast Cancer [80]
Tucatinib + Capecitabine DC50TGP Tucatinib Breast Cancer [81]
Varlitinib + Capecitabine DCCY86L Varlitinib Biliary Tract Cancer [82]
Capecitabine + Pyrotinib DC3S2UI Pyrotinib HER2 Positive Metastatic Breast Cancer [83]
Eribulin + Capecitabine DCUAJZ7 Eribulin Advanced Breast Cancer [84]
Letrozole + Capecitabine DC3E3U8 Letrozole Breast Cancer [85]
Oxaliplatin + Capecitabine DC68Z3S Oxaliplatin Rectal Neoplasms Malignant [86]
Ruxolitinib + Capecitabine DCN3VF4 Ruxolitinib Pancreatic Cancer [87]
------------------------------------------------------------------------------------
⏷ Show the Full List of 85 DrugCom(s)

References

1 Capecitabine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799).
3 ClinicalTrials.gov (NCT01589419) A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
4 ClinicalTrials.gov (NCT01843725) Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
5 ClinicalTrials.gov (NCT01300962) Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
6 ClinicalTrials.gov (NCT02550743) BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
7 ClinicalTrials.gov (NCT04664829) The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
8 ClinicalTrials.gov (NCT00959946) Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
9 ClinicalTrials.gov (NCT00121277) Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
10 ClinicalTrials.gov (NCT01494155) Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
11 ClinicalTrials.gov (NCT00130507) Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
12 ClinicalTrials.gov (NCT00398879) Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
13 ClinicalTrials.gov (NCT00661102) A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
14 ClinicalTrials.gov (NCT00452673) Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
15 ClinicalTrials.gov (NCT01267240) Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
16 ClinicalTrials.gov (NCT02352831) Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
17 ClinicalTrials.gov (NCT02422199) A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
18 ClinicalTrials.gov (NCT02861300) CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
19 ClinicalTrials.gov (NCT00305643) Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
20 ClinicalTrials.gov (NCT00081224) Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
21 ClinicalTrials.gov (NCT00107276) S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
22 ClinicalTrials.gov (NCT00050167) Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
23 ClinicalTrials.gov (NCT00054457) Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
24 ClinicalTrials.gov (NCT00437294) Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
25 ClinicalTrials.gov (NCT01323530) A Confirmation Study of Eribulin in Combination With Capecitabine
26 ClinicalTrials.gov (NCT00440167) Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
27 ClinicalTrials.gov (NCT01099527) A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
28 ClinicalTrials.gov (NCT00037609) Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
29 ClinicalTrials.gov (NCT00534417) Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
30 ClinicalTrials.gov (NCT01332604) GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
31 ClinicalTrials.gov (NCT00039390) Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
32 ClinicalTrials.gov (NCT00626158) Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
33 ClinicalTrials.gov (NCT00741260) Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
34 ClinicalTrials.gov (NCT00087152) S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
35 ClinicalTrials.gov (NCT00726687) Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
36 ClinicalTrials.gov (NCT00022698) Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
37 ClinicalTrials.gov (NCT00568022) A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
38 ClinicalTrials.gov (NCT01349088) Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
39 ClinicalTrials.gov (NCT00078572) Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
40 ClinicalTrials.gov (NCT00327743) Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
41 ClinicalTrials.gov (NCT02915172) Lenvatinib and Capecitabine in Patients With Advanced Malignancies
42 ClinicalTrials.gov (NCT02210364) Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
43 ClinicalTrials.gov (NCT06156761) Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
44 ClinicalTrials.gov (NCT02244489) Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
45 ClinicalTrials.gov (NCT01776307) A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
46 ClinicalTrials.gov (NCT00040859) Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
47 ClinicalTrials.gov (NCT00058474) Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
48 ClinicalTrials.gov (NCT00632489) LBH589 in Combination With Capecitabine Plus/Minus () Lapatinib in Breast Cancer Patients
49 ClinicalTrials.gov (NCT02910843) Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
50 ClinicalTrials.gov (NCT01423604) Study of Ruxolitinib in Pancreatic Cancer Patients
51 ClinicalTrials.gov (NCT01134601) A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
52 ClinicalTrials.gov (NCT03473639) A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
53 ClinicalTrials.gov (NCT00662025) Study Of Sunitinib With Capecitabine In Breast Cancer
54 ClinicalTrials.gov (NCT00570908) Brain Mets - Capecitabine Plus Sunitinib and WBRT
55 ClinicalTrials.gov (NCT00869050) Capecitabine and Temozolomide for Neuroendocrine Cancers
56 ClinicalTrials.gov (NCT03213002) Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
57 ClinicalTrials.gov (NCT01573468) Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
58 ClinicalTrials.gov (NCT02025192) A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
59 ClinicalTrials.gov (NCT01898104) Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer
60 ClinicalTrials.gov (NCT03082053) A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
61 ClinicalTrials.gov (NCT04274933) A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
62 ClinicalTrials.gov (NCT00450515) Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer
63 ClinicalTrials.gov (NCT00077363) Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
64 ClinicalTrials.gov (NCT05089643) Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
65 ClinicalTrials.gov (NCT04464174) Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
66 ClinicalTrials.gov (NCT01993472) Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer
67 ClinicalTrials.gov (NCT05062317) ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
68 ClinicalTrials.gov (NCT01887288) Capecitabine With Digoxin for Metastatic Breast Cancer
69 ClinicalTrials.gov (NCT05833919) Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
70 ClinicalTrials.gov (NCT02767752) Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
71 ClinicalTrials.gov (NCT00216086) Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
72 ClinicalTrials.gov (NCT01843452) Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal
73 ClinicalTrials.gov (NCT02780700) Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
74 ClinicalTrials.gov (NCT03817411) Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
75 ClinicalTrials.gov (NCT02474186) Phase II Study for Solid Metastatic Tumors
76 ClinicalTrials.gov (NCT04034251) Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
77 ClinicalTrials.gov (NCT02955940) An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
78 ClinicalTrials.gov (NCT03114085) Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
79 ClinicalTrials.gov (NCT03609489) A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma
80 ClinicalTrials.gov (NCT03858972) Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
81 ClinicalTrials.gov (NCT04721977) A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
82 ClinicalTrials.gov (NCT03093870) Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
83 ClinicalTrials.gov (NCT02973737) A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
84 ClinicalTrials.gov (NCT05063786) Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
85 ClinicalTrials.gov (NCT02767661) Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
86 ClinicalTrials.gov (NCT04103697) Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer
87 ClinicalTrials.gov (NCT02119663) A Study of Ruxolitinib in Pancreatic Cancer Patients